Uncategorized

Summit pulls $500M share sale a day after announcing it

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

Read More

Published

on

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version